Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma ( ACC ) of all Anatomic Sites of Origin and Other Malignant Salivary Gland Tumors
Cancer Medicine · 2025-04 · 14 (7)
DOI: 10.1002/cam4.70724 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer Medicine, 2025-04. Verfasst von Young Kwang Chae und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Northwestern University, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Nivolumab, Salivary Gland Neoplasms, Carcinoma, Adenoid Cystic, Ipilimumab. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb Foundation.
Abstract (Originalsprache)
Objective
Dual checkpoint inhibitor therapy with nivolumab and ipilimumab has been FDA approved for a number of cancer sites. However, its role in the treatment of ACC and non‐ACC salivary gland carcinomas (non‐ACC SGC) is not well established. Methods and Analysis We performed Simon's two‐stage prospective single‐institution Phase II clinical trial of nivolumab with ipilimumab. Two cohorts were analyzed: patients with metastatic/recurrent ACC and patients with non‐ACC SGC. The primary endpoint was median progression‐free survival (PFS); secondary endpoints were overall response rate (ORR), overall survival (OS), and toxicity.
Results
Patient enrollment was prematurely terminated due to funding constraints. In total, 19 patients with ACC and 5 patients with non‐ACC SGC were enrolled. The patients with ACC had a median OS of 30.0 months (95% CI 15.3‐NR months), a median PFS of 8.3 months (95% CI 5.5–30.0 months), and a disease control rate (DCR) of 53% (10/19). The ORR in the ACC group was 5% (CR 0%, n = 0; confirmed PR 5%, n = 1), with one patient having continued stable disease at the time of trial conclusion. The patients with non‐ACC SGC had a median OS of 10.4 months (95% CI 6.21‐NR months), a median PFS of 6.21 months (95% CI 2.83‐NR months), and a DCR of 40% (2/5). The ORR in this cohort was 0%.
Conclusion
In patients with recurrent or metastatic ACC and non‐ACC SGC, the combination of nivolumab with ipilimumab resulted in moderate disease control. Further studies are warranted to validate our findings. Trial number: NCT03146650.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Oncology, Northwestern University, Chicago, Illinois, USA.
- Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
- Department of Surgical Pathology, Northwestern University, Chicago, Illinois, USA.
- Lunit, Seoul, Republic of Korea.
- Astellas Pharmaceuticals, Northbrook, Illinois, USA.
- Department of Medical Oncology, City of Hope, Los Angeles, California, USA.
ORCID-Profile: Richard Duan, Liam Il-Young Chung, Youjin Oh
Förderung
- Bristol Myers Squibb Foundation
Zitieren
APA
Chae, Y. K., Duan, R., Chung, L. I., Oh, Y., Alexiev, B., Shin, S., Kim, S., Helenowski, I., Matsangou, M., Villaflor, V., & Mahalingam, D. (2025). Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma ( ACC ) of all Anatomic Sites of Origin and Other Malignant Salivary Gland Tumors. Cancer Medicine, 14(7). https://doi.org/10.1002/cam4.70724
Vancouver
Chae YK, Duan R, Chung LI, Oh Y, Alexiev B, Shin S, et al. Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma ( ACC ) of all Anatomic Sites of Origin and Other Malignant Salivary Gland Tumors. Cancer Medicine. 2025;14(7). doi:10.1002/cam4.70724
BibTeX
@article{Chae2025,
author = {Chae, Young Kwang and Duan, Richard and Chung, Liam Il-Young and Oh, Youjin and Alexiev, Borislav and Shin, Sangwon and Kim, Sukjun and Helenowski, Irene and Matsangou, Maria and Villaflor, Victoria and Mahalingam, Devalingam},
title = {Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma ( ACC ) of all Anatomic Sites of Origin and Other Malignant Salivary Gland Tumors},
journal = {Cancer Medicine},
year = {2025},
volume = {14},
number = {7},
doi = {10.1002/cam4.70724}
}
EUVIMED